UCB (OTCMKTS:UCBJF) Reaches New 1-Year High - Here's What Happened

Key Points

• UCB SA shares reached a new 52-week high of $269.59, a significant increase from its previous close of $238.49, with a volume of 327 shares traded.
• Wall Street analysts maintain a consensus rating of "Buy" for UCB, with Morgan Stanley reiterating an "overweight" rating in their recent report.
• The company specializes in developing biopharmaceutical solutions for neurology and immunology diseases, with key products including Cimzia and Vimpat.

UCB SA (OTCMKTS:UCBJF - Get Free Report) shares hit a new 52-week high during trading on Monday . The stock traded as high as $269.59 and last traded at $269.59, with a volume of 327 shares traded. The stock had previously closed at $238.49.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley reiterated an "overweight" rating on shares of UCB in a report on Monday, September 8th. One research analyst has rated the stock with a Buy rating, According to MarketBeat, UCB has a consensus rating of "Buy".

UCB Trading Up 11.3%

The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. The firm's 50-day simple moving average is $231.36 and its 200-day simple moving average is $196.67.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.